TME Pharma announces enrollment of first patient in pembrolizumab expansion arm of NOX‑A12 GLORIA Phase 1/2 brain cancer clinical trial
TME Pharma N.V., (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treat…